<DOC>
	<DOCNO>NCT02107833</DOCNO>
	<brief_summary>: This Phase I , study evaluate safety pharmacokinetics oral OPRX-106 healthy volunteer . Up 18 healthy male subject ( age 18 year old ) randomize one three dose cohort ( 6 subject per cohort ) , receive OPRX-106 dos equivalent 2mg , 8mg 16mg Tumor Necrosis Factor receptor-Fc fusion protein . Subjects receive daily oral administration OPRX-106 5 consecutive day . Subjects remain clinical center 24 hour first administration ( Day 1 ) OPRX-106 include PK sample return site daily additional administration study procedure .</brief_summary>
	<brief_title>Study Evaluate Safety Pharmacokinetics Oral OPRX-106 ( TNFR-Fc Fusion Protein ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Etanercept</mesh_term>
	<criteria>Healthy male age 1845 Body mass index ( BMI ) 1830 kg/m2 Male subject partner must use adequate method contraception time study . Negative laboratory test HIV , HBcAb HCV screen visit Na√Øve previous recombinant protein therapy Provide write informed consent Have ability understand requirement study comply study protocol dose regimen Clinical evidence active significant disease could potentially compromise ability Investigator evaluate interpret effect study treatment safety assessment , thus increase risk subject unacceptable level Presence acute chronic diseases History allergy proteindrug hypersensitivity Exposure longterm steroid treatment within last 12 month prior study Subject major operation last 6 month Subject receive immunosuppressive treatment prior study Chronic use medication include vitamin Participation another clinical trial previous 3 month ( subject report ) Reported history alcohol drug abuse Subjects short bowel ( 1 remove small bowel ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>